These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 25900621)

  • 41. The RASopathies as an example of RAS/MAPK pathway disturbances - clinical presentation and molecular pathogenesis of selected syndromes.
    Bezniakow N; Gos M; Obersztyn E
    Dev Period Med; 2014; 18(3):285-96. PubMed ID: 25182392
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The RASopathies: from pathogenetics to therapeutics.
    Hebron KE; Hernandez ER; Yohe ME
    Dis Model Mech; 2022 Feb; 15(2):. PubMed ID: 35178568
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Craniofacial and dental development in cardio-facio-cutaneous syndrome: the importance of Ras signaling homeostasis.
    Goodwin AF; Oberoi S; Landan M; Charles C; Groth J; Martinez A; Fairley C; Weiss LA; Tidyman WE; Klein OD; Rauen KA
    Clin Genet; 2013 Jun; 83(6):539-44. PubMed ID: 22946697
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Malignancy in Noonan syndrome and related disorders.
    Smpokou P; Zand DJ; Rosenbaum KN; Summar ML
    Clin Genet; 2015 Dec; 88(6):516-22. PubMed ID: 25683281
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Recent developments in neurofibromatoses and RASopathies: management, diagnosis and current and future therapeutic avenues.
    Rauen KA; Huson SM; Burkitt-Wright E; Evans DG; Farschtschi S; Ferner RE; Gutmann DH; Hanemann CO; Kerr B; Legius E; Parada LF; Patton M; Peltonen J; Ratner N; Riccardi VM; van der Vaart T; Vikkula M; Viskochil DH; Zenker M; Upadhyaya M
    Am J Med Genet A; 2015 Jan; 167A(1):1-10. PubMed ID: 25393061
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Costello and cardio-facio-cutaneous syndromes: Moving toward clinical trials in RASopathies.
    Rauen KA; Banerjee A; Bishop WR; Lauchle JO; McCormick F; McMahon M; Melese T; Munster PN; Nadaf S; Packer RJ; Sebolt-Leopold J; Viskochil DH
    Am J Med Genet C Semin Med Genet; 2011 May; 157C(2):136-46. PubMed ID: 21495172
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Noonan syndrome and related disorders: dysregulated RAS-mitogen activated protein kinase signal transduction.
    Gelb BD; Tartaglia M
    Hum Mol Genet; 2006 Oct; 15 Spec No 2():R220-6. PubMed ID: 16987887
    [TBL] [Abstract][Full Text] [Related]  

  • 48. First International Conference on RASopathies and Neurofibromatoses in Asia: Identification and advances of new therapeutics.
    Rauen KA; Alsaegh A; Ben-Shachar S; Berman Y; Blakeley J; Cordeiro I; Elgersma Y; Evans DG; Fisher MJ; Frayling IM; George J; Huson SM; Kerr B; Khire U; Korf B; Legius E; Messiaen L; van Minkelen R; Nampoothiri S; Ngeow J; Parada LF; Phadke S; Pillai A; Plotkin SR; Puri R; Raji A; Ramesh V; Ratner N; Shankar SP; Sharda S; Tambe A; Vikkula M; Widemann BC; Wolkenstein P; Upadhyaya M
    Am J Med Genet A; 2019 Jun; 179(6):1091-1097. PubMed ID: 30908877
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Cardiofaciocutaneous syndrome, a Noonan syndrome related disorder: clinical and molecular findings in 11 patients].
    Carcavilla A; García-Miñaúr S; Pérez-Aytés A; Vendrell T; Pinto I; Guillén-Navarro E; González-Meneses A; Aoki Y; Grinberg D; Ezquieta B
    Med Clin (Barc); 2015 Jan; 144(2):67-72. PubMed ID: 25194980
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Orthopaedic conditions in Ras/MAPK related disorders.
    Reinker KA; Stevenson DA; Tsung A
    J Pediatr Orthop; 2011; 31(5):599-605. PubMed ID: 21654472
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Mutation and phenotypic spectrum in patients with cardio-facio-cutaneous and Costello syndrome.
    Schulz AL; Albrecht B; Arici C; van der Burgt I; Buske A; Gillessen-Kaesbach G; Heller R; Horn D; Hübner CA; Korenke GC; König R; Kress W; Krüger G; Meinecke P; Mücke J; Plecko B; Rossier E; Schinzel A; Schulze A; Seemanova E; Seidel H; Spranger S; Tuysuz B; Uhrig S; Wieczorek D; Kutsche K; Zenker M
    Clin Genet; 2008 Jan; 73(1):62-70. PubMed ID: 18042262
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Gain-of-function mutations in RIT1 cause Noonan syndrome, a RAS/MAPK pathway syndrome.
    Aoki Y; Niihori T; Banjo T; Okamoto N; Mizuno S; Kurosawa K; Ogata T; Takada F; Yano M; Ando T; Hoshika T; Barnett C; Ohashi H; Kawame H; Hasegawa T; Okutani T; Nagashima T; Hasegawa S; Funayama R; Nagashima T; Nakayama K; Inoue S; Watanabe Y; Ogura T; Matsubara Y
    Am J Hum Genet; 2013 Jul; 93(1):173-80. PubMed ID: 23791108
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The RASopathy Family: Consequences of Germline Activation of the RAS/MAPK Pathway.
    Tajan M; Paccoud R; Branka S; Edouard T; Yart A
    Endocr Rev; 2018 Oct; 39(5):676-700. PubMed ID: 29924299
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Neurofibromatosis-Noonan syndrome: case report and clinicopathogenic review of the Neurofibromatosis-Noonan syndrome and RAS-MAPK pathway.
    Reig I; Boixeda P; Fleta B; Morenoc C; Gámez L; Truchuelo M
    Dermatol Online J; 2011 Apr; 17(4):4. PubMed ID: 21549079
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Costello syndrome: a Ras/mitogen activated protein kinase pathway syndrome (rasopathy) resulting from HRAS germline mutations.
    Gripp KW; Lin AE
    Genet Med; 2012 Mar; 14(3):285-92. PubMed ID: 22261753
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Stops along the RAS pathway in human genetic disease.
    Bentires-Alj M; Kontaridis MI; Neel BG
    Nat Med; 2006 Mar; 12(3):283-5. PubMed ID: 16520774
    [No Abstract]   [Full Text] [Related]  

  • 57. KRAS gene mutations in Noonan syndrome familial cases cluster in the vicinity of the switch II region of the G-domain: report of another family with metopic craniosynostosis.
    Brasil AS; Malaquias AC; Kim CA; Krieger JE; Jorge AA; Pereira AC; Bertola DR
    Am J Med Genet A; 2012 May; 158A(5):1178-84. PubMed ID: 22488932
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pathogenesis of Growth Failure in Rasopathies.
    Aftab S; Dattani MT
    Pediatr Endocrinol Rev; 2019 May; 16(Suppl 2):447-458. PubMed ID: 31115196
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Advancing RAS/RASopathy therapies: An NCI-sponsored intramural and extramural collaboration for the study of RASopathies.
    Gross AM; Frone M; Gripp KW; Gelb BD; Schoyer L; Schill L; Stronach B; Biesecker LG; Esposito D; Hernandez ER; Legius E; Loh ML; Martin S; Morrison DK; Rauen KA; Wolters PL; Zand D; McCormick F; Savage SA; Stewart DR; Widemann BC; Yohe ME
    Am J Med Genet A; 2020 Apr; 182(4):866-876. PubMed ID: 31913576
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The RASopathies: Biology, genetics and therapeutic options.
    Longo JF; Carroll SL
    Adv Cancer Res; 2022; 153():305-341. PubMed ID: 35101235
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.